key: cord-0687352-b5a92e5d
authors: Chen, Xudan; Zhu, Baoyi; Hong, Wenxin; Zeng, Jianwen; He, Xi; Chen, Jingfeng; Zheng, Haipeng; Qiu, Shuang; Deng, Ying; Chan, Juliana CN; Wang, Jian; Zhang, Yuying
title: Associations of Clinical Characteristics and Treatment Regimens with Viral RNA Shedding Duration in Patients with COVID-19
date: 2020-06-30
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.06.091
sha: 4bccb4fc03dd51fc19bd00c2abb3804cebf36790
doc_id: 687352
cord_uid: b5a92e5d

Abstract Objective The novel coronavirus disease 2019 (COVID-19) has become a global pandemic, but the factors influencing viral RNA shedding remain unclear to inform optimal control strategies. Methods The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were retrospectively evaluated. Results The median viral RNA shedding duration was 12 days (interquartile range, 8–16 d) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA cleared within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio [HR], 0.99; 95% confidence interval [CI]: 0.98–1.00; P = 0.04), time lag from illness onset to hospital admission (HR, 0.91; 95% CI: 0.88–0.94; P < 0.001), diarrhea (HR, 0.59; 95% CI: 0.36–0.96; P = 0.036), corticosteroid treatment (HR, 0.60; 95% CI: 0.39–0.94; P = 0.024), and lopinavir/ritonavir use (HR, 0.70; 95% CI: 0.52–0.94; P = 0.014) were significantly independently associated with prolonged viral RNA shedding. Conclusions Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding.

At the end of 2019, a new type of pneumonia caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), also known as COVID-19, first emerged in Wuhan, China. It spread rapidly throughout China and became a global pandemic [1] [2] [3] [4] , posing enormous challenges to global public health.

The duration of viral shedding is critical for determining control strategies to manage the disease and to reduce transmission. Several small-scale studies have reported on the viral RNA shedding pattern of SARS-CoV-2 [5, 6] . Hu et al found that 10 .2%, 62.7%, and 91.2% of patients with COVID-19 showed viral RNA negative conversation within 7 days, 14 days, and 21 days, respectively, after the first positive reverse transcription-polymerase chain reaction test [5] . Xu et al reported a median SARS-CoV-2 RNA shedding duration of 15 days after the onset of illness and that prolonged viral RNA shedding was independently associated with male sex, delayed hospital admission, and invasive mechanical ventilation [6] . Prolonged viral RNA shedding was also observed after steroid treatment although the effect rendered insignificant after controlling for confounders [6] . However, these studies were limited by small sample sizes and might have insufficient power to identify other significant risk factors associated with the duration of viral RNA shedding. Therefore, further in-depth studies are warranted to characterize the viral RNA shedding pattern and identify associated risk factors for optimizing disease control strategies. According to the Chinese COVID-19 guidelines [11] , the severity of COVID-19 infection was grouped into 4 categories: mild, moderate, serious, and critical illness.

Patients with mild illness did not demonstrate findings on chest computed tomography (CT). Those with moderate illness showed features of pneumonia on chest CT, but the symptoms were mild. Serious illness was defined by the presence of at least 1 of the following criteria: (1) breathing rate higher than 30/minute; (2) pulse oximeter oxygen saturation (SaO2) less than 93% at rest; and (3) ratio of partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) less than 300 mmHg (1 mmHg = 0.133 kPa). Critical illness was defined by presence of at least 1 Patients fulfilling all of the following criteria were discharged: (1) afebrile for more than 3 days, (2) improved respiratory symptoms, (3) resolution of infiltration shadows on pulmonary imaging, and (4) clearance of viral RNA. The latter was defined if a nuclear acid test was negative in at least 2 sequential respiratory tract samples collected at more than a 24-hour interval [11] . In our study, the viral RNA tests in respiratory tract samples were repeated every 2 days starting with the day of admission, and the first negative test date of sequential negative tests was defined as the viral RNA cleared day.

The records of patients with COVID-19 infection were extracted from the hospital's electronic medical system. Demographic, clinical, laboratory, imaging, and treatment data were collected and reviewed by trained physicians.

Statistical analysis was performed using the IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY). Continuous variables were expressed as median (interquartile J o u r n a l P r e -p r o o f range [IQR]), and categorical variables were expressed as number (%). The Breslow test was used to evaluate the impact of demographic and clinical factors on the duration of viral RNA shedding. Variables with a P value of less than 0.05 in the univariate test were included in the multivariable Cox-regression model. A P value of less than 0.05 (2-tailed) was considered statistically significant.

Overall, 284 patients were admitted to our hospital during the study period, accounting for 82% of the confirmed cases in Guangzhou (n = 347) during this period. After excluding 2 recovered patients without valid viral RNA cleared dates, 2 patients who were transferred to the hospital with viral RNA shedding, and 13 asymptomatic individuals whose illness onset dates were not clear (median duration of viral shedding was 5 days [IQR, 3-9 d] since first positive test), a total 267 patients were included in the current study (Fig. 1 ). The median age was 49 years old (IQR, 34-62 y), and 3 patients were adolescents (age, <16 y). A total of 121 (45.3%) patients were male, and 24 (9.0%) patients were smokers. The estimated median incubation period was 6 days (IQR, 4-9 d), and the median time lag from illness onset to hospital admission was 4 days (IQR, 2-7 d).

Among these patients, 166 (62.2%) had a history of exposure to the area of the J o u r n a l P r e -p r o o f epicenter (Hubei province) or close contact with people from Hubei. Of the patients, 105 (39.3%) had at least one comorbidity, including hypertension (21.3%), diabetes (8.6%), cardiovascular diseases (7.5%), and malignancy (1.9%). Fever (67.0%) and cough (58.4%) were the most common symptoms. The majority of patients (66.3%) had normal body temperature at the time of hospital admission ( Table 1 ). More than half of the patients (60.3%) had elevated D-dimer levels, and 37.6% had elevated procalcitonin levels. Decreased lymphocyte count was observed in 33.7% of patients (Table 2 ). According to the severity of clinical manifestation and chest imaging, 26 (9.7%) patients were considered mild , 197 (73.8%) were moderate, 40 (15.0%) were serious, and 4 (1.5%) were critically ill. No significant differences were observed in disease severity based on sex and smoking status. Older age, comorbid disease, and delayed hospital admission were more likely to result in serious and critical illness (Supplementary Table S1 ).

Most patients received antibiotics treatment (75.3%) and oxygen therapy (66.7%). Two (1.4%) patients received mechanical ventilation, and 22 (8.2%) patients were admitted to the ICU. Twenty-nine (10.9%) patients were treated with corticosteroid. Lopinavir/ritonavir was the most frequently used antiviral drug and was used in 28.1% of patients, followed by arbidol (24.7%), oseltamivir (13.1%), and chloroquine (9.0%) ( Table 3) . 

We compared the duration of viral shedding by demographic and clinical characteristics. As shown in Tables 1 to 3, the time lag from illness onset to hospital admission, older age, disease severity, diarrhea as a symptom, high lactic acid level, reduced serum albumin level, ICU care, oxygen therapy, use of antibiotics, corticosteroid treatment, and use of lopinavir/ritonavir were associated with prolonged viral shedding in the univariate analysis. However, in the multivariable cox-regression analysis, only age, time lag between illness onset and hospital admission, diarrhea as a symptom, corticosteroid treatment, and lopinavir/ritonavir use remained significantly associated with delayed viral RNA clearance (Table 4 ). Older age and time lag from illness onset to hospital admission were two major determinants of the persistence of viral RNA. Although the immune system weakens with aging [12] , delayed hospital admission might result in disease progression, especially in older patients. Indeed, more than 34% of patients in this cohort who were 65 years or older experienced serious or critical illness. Therefore, special attention should be given to older patients who tend to have more severe illness.

Corticosteroid treatment has been reported to be associated with prolonged viral RNA shedding in patients with Middle East Respiratory Syndrome [13] and SARS [14] in observational studies. Xu et al reported that corticosteroid use was also associated with prolonged viral RNA shedding in patients with COVID-19, although the effect was rendered insignificant in the multivariable models [6] , probably J o u r n a l P r e -p r o o f partially owing to an insufficient sample size to detect the difference. In line with previous reports [15, 16] , our analysis indicated that corticosteroid use was independently associated with delayed viral RNA clearance even after controlling for major confounders, including age and disease severity, calling for its cautious use in patients with COVID-19.

Lopinavir/ritonavir is a fixed dose combination of anti-human immunodeficiency virus protease inhibitors acting against the viral 3CL protease [17] . Although it has been used to treat COVID-19 [11] , no benefits were observed with lopinavir/ritonavir compared with standard care in a clinical controlled trial involving patients with severe COVID-19 in Wuhan [18]. Our findings were in line with the controlled trial.

Moreover, apart from lack of benefit, the use of lopinavir/ ritonavir tended to delay viral RNA clearance, even after controlling for confounding factors, including disease severity. The slightly different findings between these two studies might be explained by the fact that most patients in our cohort had moderate illness. In support of our perspective, the median viral RNA shedding duration was significantly longer in cases of mild-to-moderate illness treated with lopinavir/ ritonavir (14. Therefore, the prolonged viral RNA shedding associated with diarrhea as a symptom might reflect a higher viral burden in these patients. Given the growing number of patients with COVID-19 infection, our data suggested that particular attention should be given to patients with diarrhea as a symptom.

In this study, the majority of patients had viral RNA cleared within 3 weeks, which was consistent with other reports [5, 6] . However, a small proportion of patients had viral shedding for more than one month, even in patients with mild illness.

Although detectable viral RNA did not mean transmissibility, the prolonged viral shedding reinforced the importance of continued isolation for recovered patients. In support of our perspective, the Chinese Guideline suggested at least 14 days of continued isolation for COVID-19 patients after discharge, which was found to have a satisfactory effect on reducing re-transmission [11].

The median duration of viral shedding after the onset of illness was 12 days in this study. This was compared to 15 days reported by Xu et al [6] , which might reflect the less severe nature of our patients. Additionally, the difference might be attributed to the shorter time from the onset of illness to hospital admission in our study (4 d There were some limitations in this study. First, the viral RNA test was repeated every 2 days after hospitalization. Therefore, the viral RNA shedding duration might have some bias. Second, owing to the small sample size and the observational nature of the study, our data regarding treatment efficacy of antiviral drugs should be interpreted with caution. Third, our patients had predominately moderate illness and J o u r n a l P r e -p r o o f the results might not apply to patients with serious or critical illness. Lastly, our study was conducted as a retrospective single-center study. However, our hospital managed more than 80% of the confirmed COVID-19 cases in the Guangzhou area and the findings from this cohort should represent the epidemical features of COVID-19 in that area.

In conclusion, older age, delayed hospital admission, diarrhea as a symptom, corticosteroid use, and lopinavir/ritonavir use were independently associated with 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Clinical Characteristics of Coronavirus Disease 2019 in China

The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat

Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Aging and the immune system: An overview

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

On the use of corticosteroids for 2019-nCoV pneumonia

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

Data were presented as number (%) for categorical variables, and median (interquartile range) for continuous variables

Breslow test was used to compare the difference in viral RNA shedding duration by groups

We thank all patients and care providers who participated in this study.

The authors declare no conflict of interests.J o u r n a l P r e -p r o o f